07:59 AM EST, 12/03/2024 (MT Newswires) -- Aptose Biosciences ( APTO ) , a precision oncology company, on Tuesday said it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

The NCI and Aptose will collaborate on developing Aptose's compound tuspetinib (TUS), an inhibitor of key signaling kinases involved in certain malignancies, in the NCI-sponsored myeloMATCH trials.

The myeloMATCH trials, launched this year, aims to develop tailored drug combination treatments for patients with newly diagnosed AML and MDS cancers, and to treat patients with these cancers of the blood and bone marrow from diagnosis throughout their treatment journey.

"We're grateful to be a part of NCI's myeloMATCH precision medicine trials," Aptose Chief Executive William Rice said. "The executed CRADA will facilitate our collaboration with NCI on clinical studies of novel-novel combinations with early phase II signal finding endpoints in AML and MDS."